MedTrace Logo

Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy

NCT00383812 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2006-10-04

No results posted yet for this study

Summary

1. Primary objectives

a. To evaluate the Effects of intravitreal Bevacizumab on polypoidal choroidal vasculopathy(PCV)
2. Secondary objectives

1. To assess the changes in visual acuity
2. To assess the change in lesion characteristics of PCV

* size of PCV
* fluorescein leakage
* foveal thickness
3. To investigate the safety of intravitreal Bevacizumab in patients with PCV
4. To assess the effect of intravitreal Bevacizumab on the recurrence rate and the the incidence of submacular hemorrhage in patients with PCV

Conditions

  • Polypoidal Choroidal Vasculopathy

Interventions

DRUG

Intravitreal Bevacizumab

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Young Hee Yoon, MD · Asan Medical Center

  • June-Gone Kim, MD · Asan Medical Center

  • Sun Young Lee, MD · Asan Medical Center

  • Hyewon Chung, MD · Asan Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Completion
2008-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00383812 on ClinicalTrials.gov